The tolterodine market has been expanding due to its use in treating overactive bladder (OAB) and urinary incontinence, common conditions affecting a significant portion of the global population, especially in the elderly. Tolterodine is an antimuscarinic medication that helps control bladder spasms by relaxing the muscles of the bladder. As demand for effective treatments for overactive bladder treatment OAB grows, tolterodine has gained popularity for its efficacy and safety profile. Recent developments in the market include the introduction of extended-release formulations, improving patient compliance and reducing side effects. The increasing awareness of urinary disorders, along with the availability of tolterodine in both branded and generic forms, has contributed to market growth. In addition, advancements in drug delivery systems and ongoing research into alternative treatments are expected to further drive the market. However, challenges such as side effects and competition from other OAB drugs may limit market expansion in certain regions.
